HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals?
- PMID: 28742943
- DOI: 10.1111/ajt.14447
HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals?
Keywords: cirrhosis; clinical research/practice; donors and donation:donor-derived infections; donors and donation:extended criteria; infection and infectious agents - viral: hepatitis C; liver transplantation/hepatology; organ acceptance; organ procurement and allocation.
Comment in
-
Response to: HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals?Am J Transplant. 2017 Nov;17(11):2988. doi: 10.1111/ajt.14478. Epub 2017 Sep 23. Am J Transplant. 2017. PMID: 28858416 No abstract available.
Comment on
-
The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.Am J Transplant. 2017 Nov;17(11):2790-2802. doi: 10.1111/ajt.14381. Epub 2017 Jul 1. Am J Transplant. 2017. PMID: 28556422
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
